- Home
- BIIB vs VLTO Comparison
BIIB vs VLTO Comparison
Compare BIIB & VLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- VLTO
- Stock Information
- Founded
- BIIB 1978
- VLTO 2023
- Country
- BIIB United States
- VLTO United States
- Employees
- BIIB N/A
- VLTO N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- VLTO Electrical Products
- Sector
- BIIB Health Care
- VLTO Industrials
- Exchange
- BIIB Nasdaq
- VLTO Nasdaq
- Market Cap
- BIIB 18.8B
- VLTO 25.1B
- IPO Year
- BIIB 1991
- VLTO N/A
- Fundamental
- Price
- BIIB $135.28
- VLTO $102.44
- Analyst Decision
- BIIB Buy
- VLTO Buy
- Analyst Count
- BIIB 27
- VLTO 10
- Target Price
- BIIB $188.17
- VLTO $110.10
- AVG Volume (30 Days)
- BIIB 1.2M
- VLTO 1.2M
- Earning Date
- BIIB 07-31-2025
- VLTO 07-24-2025
- Dividend Yield
- BIIB N/A
- VLTO 0.43%
- EPS Growth
- BIIB 26.39
- VLTO 8.36
- EPS
- BIIB 10.12
- VLTO 3.50
- Revenue
- BIIB $9,816,400,000.00
- VLTO $5,279,000,000.00
- Revenue This Year
- BIIB N/A
- VLTO $6.10
- Revenue Next Year
- BIIB N/A
- VLTO $4.70
- P/E Ratio
- BIIB $13.29
- VLTO $29.24
- Revenue Growth
- BIIB 1.59
- VLTO 4.70
- 52 Week Low
- BIIB $110.04
- VLTO $83.87
- 52 Week High
- BIIB $238.00
- VLTO $115.00
- Technical
- Relative Strength Index (RSI)
- BIIB 61.69
- VLTO 60.63
- Support Level
- BIIB $129.08
- VLTO $96.46
- Resistance Level
- BIIB $134.75
- VLTO $104.05
- Average True Range (ATR)
- BIIB 3.74
- VLTO 1.64
- MACD
- BIIB 0.65
- VLTO 0.26
- Stochastic Oscillator
- BIIB 82.50
- VLTO 78.79
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About VLTO Veralto Corp
Veralto is a diversified industrial firm organized into two segments, water quality as well as product quality and innovation. The water quality segment offers water analytics and water treatment solutions, while the product quality and innovation segment offers coding, packaging, and color solutions for consumer packaged goods and pharmaceuticals. Headquartered in Waltham, Massachusetts, the company has around 17,000 employees. Veralto generated approximately $5.2 billion in revenue in 2024.